Fig 1.
Expression and diagnostic value of DEPDC1 based on TCGA data.
(A) Boxplots of DEPDC1 expression in LUAD. (B) Identification of DEPDC1 expression in pairs of LUAD samples. (C) The ROC curve of DEPDC1 in LUAD. (D) Boxplots of DEPDC1 expression in LUSC. (E) Identification of DEPDC1 expression in pairs of LUSC samples. (F) The ROC curve of DEPDC1 in LUSC. (G) Boxplots of DEPDC1 expression in NSCLC. (H) Identification of DEPDC1 expression in pairs of NSCLC samples. (I) The ROC curve of DEPDC1 in NSCLC.
Fig 2.
The heatmap of the clinical features of cases in the low- and high-DEPDC1 expression group in the TCGA cohort.
(*P < 0.05, **P < 0.01, ***P < 0.001). (A) LUAD. (B) LUSC. (C) NSCLC.
Table 1.
Features of the eligible gene expression omnibus datasets.
Fig 3.
Continuous variable meta-analysis of GEO data.
(A) Forest plot. (B) Sensitivity analysis. (C) Subgroup analysis based on cancer type. (D) Funnel plot.
Table 2.
Relationship between the expression of DEPDC1 and clinicopathological features in NSCLC patients from GEO.
Fig 4.
DEPDC1 expression in NSCLC and ROC curves of DEPDC1 based on GEO datasets.
(A-J) DEPDC1 expression in NSCLC. (K-T) ROC curves of DEPDC1.
Fig 5.
Forest plots and the sROC curve based on GEO and TCGA data.
(A) Forest plot of sensitivity. (B) Forest plot of specificity. (C) Forest plot of positive likelihood ratio. (D) Forest plot of negative likelihood ratio. (E) Forest plot of odds ratio. (F) The sROC curve.
Fig 6.
Immunohistochemical analysis of DEPDC1 in the HPA-derived normal, LUSC and LUAD samples.
Fig 7.
DEPDC1 inhibits NSCLC cell proliferation and enhances their apoptosis (*P < 0.05, **P < 0.01, ***P < 0.001).
(A) DEPDC1 mRNA expression within BEAS-2B and NCI-H1299 cells. (B) DEPDC1 protein expression within BEAS-2B and NCI-H1299 cells. (C) DEPDC1 mRNA expression within NCI-H1299 cells after siRNA-NC and siRNA-DEPDC1 transfection. (D) DEPDC1 protein expression within NCI-H1299 cells after siRNA-NC and siRNA-DEPDC1 transfection. (E) MTS assay conducted to analyze NCI-H1299 cell proliferation at 0/24/48/72h after siRNA-NC and siRNA-DEPDC1 transfection. (F) NCI-H1299 cell apoptosis after siRNA-NC and siRNA-DEPDC1 transfection.
Fig 8.
Relations between DEPDC1 level and tumor immune microenvironment, immune infiltrating cells and immune checkpoint inhibitors based on TCGA database (*P < 0.05, **P < 0.01, ***P < 0.001).
(A) Scatter diagrams showing the correlation between DEPDC1 expression and tumor immune microenvironment. (B) Boxplots displaying the immune infiltrating cells between the low- and high-DEPDC1 expression groups in NSCLC. (C) Lollipop plot showing the relation of DEPDC1 level with immune infiltrating cells within NSCLC. (D-G) Relation of DEPDC1 level with immune checkpoint inhibitors.
Fig 9.
Analysis of DEPDC1 signaling pathway and immune-related genes (*P < 0.05, **P < 0.01, ***P < 0.001).
(A) Gene enrichment plot of multiple pathways in GSEA. (B) Protein levels of DEPDC1, P53 and BAX in response to the treatment of siRNA-NC and siRNA-DEPDC1. (C) Deviation plot of the top 20 immune-related genes significantly associated with DEPDC1. (D) The expression levels of NRAS, TNFSF12, CD81 and BIRC5 mRNAs after the treatment of siRNA-NC and siRNA-DEPDC1. (E) GO analysis of DEPDC1 and immune-related genes. (F) KEGG pathways items of DEPDC1 and immune-related genes.